Former President Joseph R. Biden’s recent diagnosis of metastatic prostate cancer has put prostate health back into the national spotlight. His courage in sharing his diagnosis, particularly at age 82 ...

The treatment landscape for high-risk, BCG-unresponsive non–muscle-invasive bladder cancer has expanded significantly, with 3 FDA-approved bladder-sparing therapies now available: pembrolizumab, ...

The Novel Tracer 89Zr-TLX250 Main Discussion Topics: 89Zr-TLX250 is an antibody that binds to carbonic anhydrase IX (CAIX). CAIX is an enzyme expressed on the surface of most clear cell renal cell ...

Paul E. Dato, MD, discusses how bone-targeted therapies play an important supportive role in advanced prostate cancer, with recommendations for calcium and vitamin D supplementation, vitamin K2 ...

Key Takeaways Zanzalintinib and nivolumab showed a 63% response rate and 18.5-month median PFS in stage 4 RCC. The study included patients with advanced RCC, treated with zanzalintinib plus nivolumab ...

In this episode of Pearls and Perspectives, host Amy Pearlman, MD, is joined by Joshua R. Gonzalez, MD —a board-certified urologist and sexual medicine specialist based in Los Angeles, California—for ...

Diagnostic Performance of the ZIRCON Trial Main Discussion Topics: A 93% to 95% positive predictive value for clear cell renal cell carcinoma (ccRCC) A 75% negative predictive value Important ...

Bedke explained, “I think the important message is that we have no specific subgroup which will have a more pronounced benefit of EV+P if compared to the platinum-based chemotherapy. Selecting ...

Physician Summary: Overcoming Challenges in Accessing New Therapies for NMIBC Access to new therapies for non-muscle invasive bladder cancer (NMIBC) presents several challenges, including cost, ...

The cornerstone for first-line treatment in metastatic prostate cancer is androgen deprivation therapy (ADT), although there are several other options that can be used to personalize treatment to the ...

Panelists discuss emerging immunotherapy strategies for BCG-unresponsive non–muscle-invasive bladder cancer (NMIBC), particularly the combination of BCG with systemic checkpoint inhibitors, noting ...

The concept of BCG-unresponsive non–muscle-invasive bladder cancer has evolved significantly since its introduction in 2015. This designation is crucial for identifying patients who have received an ...